News
DYN
16.03
-2.91%
-0.48
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 2d ago
Is Dyne Therapeutics (DYN) Undervalued Following New ACHIEVE Trial Data Presentations?
Simply Wall St · 4d ago
Weekly Report: what happened at DYN last week (0914-0918)?
Weekly Report · 5d ago
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 09/17 15:05
What Dyne Therapeutics Stock One Year Trial Data Means For Shareholders
Simply Wall St · 09/17 05:25
Weekly Report: what happened at DYN last week (0907-0911)?
Weekly Report · 09/14 10:23
Buy/Sell: Wall Street’s top 10 stock calls this week
TipRanks · 09/11 18:10
Analysts Offer Insights on Healthcare Companies: Eocene (EOCN) and Dyne Therapeutics (DYN)
TipRanks · 09/10 18:40
Stocks Pressured as Inflation Fears Boost Bond Yields
NASDAQ · 09/09 20:22
Dyne Therapeutics Is Maintained at Overweight by Morgan Stanley
Dow Jones · 09/09 17:38
Dyne Therapeutics Price Target Cut to $36.00/Share From $45.00 by Morgan Stanley
Dow Jones · 09/09 17:38
Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $36
Benzinga · 09/09 17:28
Midday Fly By: Analog acquires Alif, Independence Realty merges with Centerspace
TipRanks · 09/09 16:05
Stocks Fall as Crude Prices Soar and Bond Yields Climb
Barchart · 09/09 15:39
Dyne Therapeutics Price Target Cut to $10.00/Share From $17.00 by JP Morgan
Dow Jones · 09/09 15:06
Dyne Therapeutics Cut to Underweight From Neutral by JP Morgan
Dow Jones · 09/09 15:06
Uber initiated, Thermo Fisher upgraded: Wall Street’s top analyst calls
TipRanks · 09/09 13:56
Dyne Therapeutics Is Maintained at Outperform by RBC Capital
Dow Jones · 09/09 13:38
Dyne Therapeutics Price Target Cut to $30.00/Share From $35.00 by RBC Capital
Dow Jones · 09/09 13:38
Dyne Therapeutics Price Target Cut to $26.00/Share From $30.00 by Baird
Dow Jones · 09/09 13:34
More
Webull provides a variety of real-time DYN stock news. You can receive the latest news about Dyne Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About DYN
Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company. It is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and central nervous system (CNS). It has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 and Duchenne muscular dystrophy and preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease. Its product candidate, zeleciment basivarsen (also known as DYNE-101), is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, zeleciment rostudirsen (also known as DYNE-251), is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to skipping exon 51. Its other product candidates are DYNE-302 and DYNE-401.